GlassScriptPhysician profile
Sara Newman
NPI 1679260715
$4,272.95
in general payments reported to CMS, 2019-2025
33 companies · $679 in 2025
The $679 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $776 · 2024: $2,817 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,828 · Travel and Lodging: $1,445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,827.80 |
| Travel and Lodging | $1,445.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,913.20 | 2024 | Vns Therapy |
| Neurocrine Biosciences, INC. | $401.61 | 2023-2025 | Ingrezza, Ongentys |
| Alexion Pharmaceuticals, INC. | $204.85 | 2023-2025 | Ultomiris |
| Biogen, INC. | $198.65 | 2023-2025 | Vumerity |
| Genentech, INC. | $163.15 | 2024-2025 | Ocrevus |
| Emd Serono, INC. | $143.21 | 2023-2024 | Mavenclad, Mavenclad |
| Abbvie INC. | $122.81 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $120.78 | 2025 | Zeposia |
| Sk Life Science, INC. | $115.90 | 2023-2024 | Xcopri |
| Acadia Pharmaceuticals INC | $94.09 | 2024 | Nuplazid |
| Pfizer INC. | $76.45 | 2023-2025 | |
| Catalyst Pharmaceuticals, INC. | $75.33 | 2023-2024 | Fycompa |
| Genentech USA, INC. | $71.29 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Takeda Pharmaceuticals U.S.A., INC. | $63.67 | 2023-2024 | Hyqvia |
| Argenx US, INC. | $54.38 | 2023-2024 | Vyvgart |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $54.10 | 2023-2025 | Symbravo, Sunosi |
| Eisai INC. | $49.21 | 2023-2024 | |
| Csl Behring | $36.41 | 2023 | Hizentra |
| Tg Therapeutics, INC. | $34.14 | 2023 | |
| Merz Pharmaceuticals, LLC | $33.01 | 2023-2025 | Xeomin, Inbrija, Ampyra |
| Boston Scientific Corporation | $29.76 | 2023 | Vercise |
| Jazz Pharmaceuticals INC. | $28.17 | 2024 | |
| Neurelis, INC. | $24.99 | 2023 | Valtoco |
| Microtransponder, INC. | $21.37 | 2024 | |
| Averitas Pharma INC. | $19.08 | 2023 | Qutenza |
| Impel Pharmaceuticals INC. | $18.38 | 2023 | Trudhesa |
| Celgene Corporation | $17.06 | 2023 | Zeposia |
| Amylyx Pharmaceuticals, INC. | $16.97 | 2023 | Relyvrio |
| Acorda Therapeutics, INC | $15.82 | 2023 | Ampyra, Inbrija |
| Alnylam Pharmaceuticals INC. | $15.20 | 2023 | Amvuttra |
| Novartis Pharmaceuticals Corporation | $13.78 | 2024 | |
| Kyowa Kirin, INC. | $13.23 | 2024 | Nourianz |
| Bio Products Laboratory USA, INC. | $12.90 | 2023 | Coagadex, Gammaplex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Newman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.